Terms: = Rhabdomyosarcoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
6 results:
1. Fusion of the Paired Box 3 (
Panagopoulos I; Gorunova L; Andersen K; Lund-Iversen M; Tafjord S; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(6):723-734. PubMed ID: 34697065
[TBL] [Abstract] [Full Text] [Related]
2. Genomic Classification and clinical outcome in rhabdomyosarcoma: A Report From an International Consortium.
Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
[TBL] [Abstract] [Full Text] [Related]
3. DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation.
Bean GR; Anderson J; Sangoi AR; Krings G; Garg K
Mod Pathol; 2019 Feb; 32(2):280-289. PubMed ID: 30266945
[TBL] [Abstract] [Full Text] [Related]
4. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior.
Staibano S; Franco R; Tranfa F; Mezza E; Lo Muzio L; Strianese D; Errico ME; Bufo P; Ferrara G; Somma P; Mansueto G; Greco I; Fiorillo A; Bonavolontà G; De Rosa G
Anticancer Res; 2004; 24(1):249-57. PubMed ID: 15015604
[TBL] [Abstract] [Full Text] [Related]
5. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS).
Smith LM; Anderson JR; Coffin CM
Med Pediatr Oncol; 2002 Jun; 38(6):398-404. PubMed ID: 11984800
[TBL] [Abstract] [Full Text] [Related]
6. p53 protein detection by the western blotting technique in normal and neoplastic specimens of human endometrium.
Bryś M; Semczuk A; Wójcik M; Krajewska WM; Jakowicki JA
Cancer Lett; 2000 Feb; 148(2):197-205. PubMed ID: 10695997
[TBL] [Abstract] [Full Text] [Related]
